NCT06167577View on ClinicalTrials.gov

Dysbindin-antipsychotics Psychophamarcogenetics: a Mouse-human Translational Study Towards Personalized Healthcare in Bipolar Disorders

CompletedOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

November 8, 2018

Primary Completion Date

February 8, 2022

Study Completion Date

November 8, 2023

Conditions
Bipolar Disorder
Interventions
DIAGNOSTIC_TEST

Psychometric scales (BPRS, MRS, HAM-D, SES, and GAF) monthly

we will correlate the clinical/neuropsychological response to antipsychotics with the presence of the functional DysBray haplotype of the DTNBP1 gene

Trial Locations (1)

20100

Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan

All Listed Sponsors
collaborator

ASST Santi Paolo e Carlo

OTHER

collaborator

Asst Melegnano e Martesana

OTHER_GOV

collaborator

Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria

OTHER

lead

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

OTHER

NCT06167577 - Dysbindin-antipsychotics Psychophamarcogenetics: a Mouse-human Translational Study Towards Personalized Healthcare in Bipolar Disorders | Biotech Hunter | Biotech Hunter